Please login to the form below
Tobira Therapeutics
This page shows the latest Tobira Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Allergan buys regenerative medicine firm LifeCell for $2.9bn
Allergan's other deals in 2016 have included a $1.7bn acquisition of Tobira Therapeutics - which gave it two drug candidates for non-alcoholic steatohepatitis (NASH) - a $639m takeover of dermatology
Latest news
-
Gilead chalks up trial success for new NASH drug
Along with selonsertib, Gilead is also developing an FXR agonist called GS-9674 in phase I trials and acquired a wholly-owned subsidiary of Nimbus Therapeutics for $1.2bn earlier this ... Allergan has been building a pipeline of candidates through a
-
Allergan buys two NASH drug developers in one day
More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics. Allergan has gone on the acquisition trail once again, stumping up more than $1.7bn for non-alcoholic steatohepatitis (NASH) ... The headline deal is the $1.69bn offered for Tobira
-
A competitive edge
TBR 652 is currently being developed by Tobira Therapeutics. A phase IIa proof-of-concept trial evaluated the antiviral activity, safety and pharmacokinetics of TBR 652 in treatment-experienced, CCR5-naïve ... Philippines. Dalfampridine . Ampyra
More from news
Approximately 3 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Hogging the headlines …. Featuring in two entries in the September Deal Watch table, Allergan was busy splashing the cash with a $1.7bn acquisition of Tobira Therapeutics, hotly followed by the ... 1, 710. Tobira Therapeutics / Allergan. Acquisition
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
